Compare PSFE & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSFE | RAPT |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.4M | 498.4M |
| IPO Year | N/A | 2019 |
| Metric | PSFE | RAPT |
|---|---|---|
| Price | $8.23 | $35.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $10.60 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 606.0K | 469.6K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,683,103,000.00 | N/A |
| Revenue This Year | $1.95 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.43 | $5.67 |
| 52 Week High | $24.11 | $42.39 |
| Indicator | PSFE | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 59.12 |
| Support Level | $7.68 | $31.70 |
| Resistance Level | $8.46 | $37.75 |
| Average True Range (ATR) | 0.37 | 2.62 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 56.70 | 61.33 |
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.